Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial

Harry Erba, Jes Hansen, Sudhir Unni, Yvonne Duong, Ahmed Ali, Kristen Tecson, Akash Nahar, Kristy Burns, Esther Natalie Oliva

Blood (2025) 146 (Supplement 1): 2650.

https://doi.org/10.1182/blood-2025-2650

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

Next-generation sequencing for myeloid malignancies: Uncovering clinical gaps in physician knowledge and practice

Victoria Harvey-Jones, Keisha Peters, Lisa Lishman, Tristin Abair, Harry Erba

Blood (2025) 146 (Supplement 1): 6422.

https://doi.org/10.1182/blood-2025-6422

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Vivian Liu, Megan Othus, Rhonda Ries, Jasmine Naru, Era Pogosova-Agadjanyan, Frederick Appelbaum, Lan Beppu, Thomas Chauncey, Harry Erba, John Godwin, Matthew Fitzgibbon, Min Fang, Stanley Lee, Anna Moseley, Jerald Radich, Cheryl Willman, Feinan Wu, Soheil Meshinchi, Derek Stirewalt

Blood (2025) 146 (Supplement 1): 6999.

https://doi.org/10.1182/blood-2025-6999

Published: 2025

Journal Articles

Real-world survival outcomes with first-line venetoclax therapy in AML

Nia M. Mitchell, Allison O. Taylor, Cheryl H. Chang, Rebecca Bystrom, Carlos de Castro, Harry Erba, Sanghee Hong, Chenyu Lin, Steven Wolf, Susan C. Locke, Thomas LeBlanc

Blood (2025) 146 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2025-1660

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Xiaoyu QU, Kate Kroeger, Jacob Wilson, Alyssa Ng, Cecilia Yeung, Shahanawaz Jiwani, Lyndsay Harris, Brent Wood, Harry Erba, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2025-3501

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening - an NCI myelomatch and SWOG report

Xiaoyu QU, Shane McClung, Nicole Shepherd, Kate Kroeger, Beverly Hale, Othus Megan, Harry Erba, Lyndsay Harris, Richard Little, Jerald Radich, Min Fang

Blood (2025) 146 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2025-3473

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Kate Kroeger, Thaiha Nguyen, Xiaoyu QU, Brent Wood, Lyndsay Harris, Harry Erba, Jerald Radich, Richard Little, Cecilia Yeung, Shahanawaz Jiwani

Blood (2025) 146 (Supplement 1): 5276.

https://doi.org/10.1182/blood-2025-5276

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric Huselton, Uma Borate, John Reagan, Richard Little, Steven Gore, Megan Othus, Anna Moseley, Manu Pandey, Xin Wang, Laura Michaelis, Geoffrey Uy, Anjali Advani, Harry Erba

Blood (2025) 146 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2025-3466

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Shahanawaz Jiwani, Min Fang, Cecilia Yeung, Xiaoyu QU, Xueyan Chen, Brent Wood, Andrea Zak, Srikrishna Narava, Ting-Chia Chang, Celso Baldivieso, Megha Kamath, Megan Othus, Bhanumati Ramineni, Harry Erba, Mark Litzow, James Doroshow, Lyndsay Harris, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 340.

https://doi.org/10.1182/blood-2025-340

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Next-generation sequencing for myeloid malignancies: Uncovering clinical gaps in physician knowledge and practice

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML

Real-world survival outcomes with first-line venetoclax therapy in AML

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening - an NCI myelomatch and SWOG report

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only